Figure 3 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer

<p>Correlative studies. <b>A,</b> Dot plot showing the correlation between CDK6 and (<b>B</b>) p-ERK staining (<i>Z</i>-score) and PFS time. The Pearson coefficients were −0.158 (<i>P</i> = 0.472) and 0.143 (<i>P</i> = 0.514). <b>C,</b> Mutational status of HR genes among patients with short (<4 months) or prolonged (>4 months) progression-free interval. Dark color indicates WT status of both alleles; green indicates a heterozygous deleterious mutation, and yellow indicates deleterious alterations in both alleles. <b>D,</b> Heatmap depicting the genes with differential mutational pattern between patients with short or long PFS, listed by their <i>T</i> test score. Darker colors indicate none or lower number of deleterious mutations across their exome, whereas lighter colors indicate increased number of deleterious mutations (up to 5).</p>